Tris Pharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
2031 US Highway 130, Monmouth Junction, ...Phone Number
(732) 940-2800Website
www.trispharma.comRevenue
$90 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About Tris Pharma
Tris Pharma is a privately owned premier pharmaceutical company focused on commercializing our branded portfolio of differentiated ADHD medications, seeking development and licensing partnerships by leveraging our novel technology platform, and growing our niche generics business.Explore more
Tris Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tris Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Tris Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Tris Pharma
Product Launch: Get notified when Tris Pharma launches new products
Check out if Tris Pharma is spiking on competitors!
Funding: Get notified immidiatlly once Tris Pharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Tris Pharma has recently received funding, and reach out quickly before it becomes old news!
Tris Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Tris Pharma recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Tris Pharma
Compare insights from companies similar to Tris Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tris Pharma
$90M
501-1,000
Private
$5M
2000
PC
Peter CianoChief Financial Officer & SVP Corporate Development
Company Profile Activity
Activity Insights
Tris Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tris Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tris Pharma.
Tris Pharma financials insights
Gather financial insights about Tris Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$5M
Tris Pharma Tech Stack
A closer look at the technologies used by Tris Pharma
See more technologies
Most Recent Scoops
Person-Based
Partnership
Person-Based
Pharmaceuticals
Person-Based
Events, Pharmaceuticals
Person-Based
Medical Education & Training
Person-Based
Pharmaceuticals
Tris Pharma News & Media
Adneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Korea
Agreement Grants Maruishi Rights for the Development and Commercialization of Cebranopadol for Pain in Japan and South Korea, Marking Adneuris' Second Ex-U.S. Licensing TransactionAdneuris Therapeutics Grants Exclusive License to Zhejiang Conba Pharmaceutical to Advance Cebranopadol in Greater China
Agreement Grants Conba Rights for the Development and Commercialization of Cebranopadol for Pain Across Mainland China, Hong Kong, Macao and Taiwan, representing an important step in expanding the global potential of cebranopadolTris Pharma Launches Adneuris Therapeutics to Advance a New Era in Pain Medicine
Tris Pharma’s Wholly-Owned Subsidiary is Advancing the Development of Cebranopadol as it Prepares for New Drug Application (NDA) Submission Later This Year Tris Pharma’s Wholly-Owned Subsidiary is Advancing the Development of Cebranopadol as it Prepares for New Drug Application (NDA) Submission Later This YearTris Pharma to Present on Dual NOP/MOP Receptor Agonist in Pain Management and Substance Use Disorder at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, 2026
MONMOUTH JUNCTION, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced five presentations on cebranopadol, an investigational dual NOP/MOP receptor agonist, in substance use disorder and pain management at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting taking place from June 13-17, 2026, in Portland, OR.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tris Pharma
Sign Up For FreeTo access detailed company insights
Tris Pharma is a privately owned premier pharmaceutical company focused on commercializing our branded portfolio of differentiated ADHD medications, seeking development and licensing partnerships by leveraging our novel technology platform, and growing our niche generics business.... Read More
